Kymab is discovering and developing fully human ...
Founded in 2009, Kymab raised $30m of equity financing in 2010 from The Wellcome Trust Investment Division to enable the development of the Kymouse™ platform and create a portfolio of therapeutic assets. In 2014, The Bill and Melinda Gates Foundation together with The Welcome Trust invested a further $40 million in Kymab. This enables their mission to advance their pipeline of first-in-class therapeutics and embark on vaccine development in areas of high unmet medical need.
The company leveraged technology developed in the laboratory of Professor Allan Bradley from The Sanger Institute, a world leading genomics research centre.
Funding and Financing Rounds
Series B / Equity
Impact Reports & Metrics
Meditrina Babraham Research
Campus Cambridge, CB22 3AT
United Kingdom of Great Britai